Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Burning mouth syndrome caused by xerostomia secondary to amlodipine

Dental Journal (Majalah Kedokteran Gigi) · Vol. 53 No. 4 (2020) · hlm. 187–190

DOI
10.20473/j.djmkg.v53.i4.p187-190
ISSN
2442-9740, 1978-3728
Terbit
2020-12-01
Penerbit
Faculty of Dental Medicine, Universitas Airlangga https://fkg.unair.ac.id/en
Bahasa
eng

Abstrak

Background: Xerostomia, generally referred to as dry mouth, has been identified as a side effect of more than 1,800 drugs from more than 80 groups. This condition is frequently unrecognised and untreated but may affect patients' quality of life and cause problems with oral and medical health, including burning mouth syndrome (BMS). Purpose: The purpose of this case is to discuss how to manage a patient with BMS caused by xerostomia secondary to medication that has been taken by the patient. Case: We reported that a 45-year-old male military officer from the Royal Malaysian Air Force came to Kuching Armed Forces Dental Clinic with dry mouth and a burning sensation since he started taking 10 mg of amlodipine due to his hypertension. After a thorough physical and history examination, we made a diagnosis of burning mouth syndrome (BMS) caused by xerostomia secondary to amlodipine. Case Management: Oral hygiene instructions, diet advice and prescription of Oral7 mouthwash has been given to reduce the symptoms of BMS. The patient has been referred to the general practitioner to reduce his amlodipine dosage from 10 mg to 5 mg (OD) in order to prevent xerostomia, and oral hygiene instructions have been given. A review after two weeks showed significant changes in the oral cavity, and the patient was satisfied as he is no longer feeling the burning sensation and can enjoy his food without feeling difficulty in chewing and swallowing. Conclusion: Adverse drug events are normal in the oral cavity and may have a number of clinical presentations such as xerostomia. Xerostomia can cause many implications as saliva helps in maintaining oral mucosa and has a protective function. The signs of adverse drug incidents in the oral cavity should be identified to oral health care professionals.

Kata kunci

Jaringan kolaborasi para penulis

26 penulis · 78 tautan kepenulisan bersama · 25 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Royal College of Surgeons of Edinburgh
  • Universitas Muhammadiyah Surabaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kun IsmiyatinUniversitas Airlangga2
James Lian Yoon ChenAfiliasi tidak diketahui1
Mohd Safwani Affan AlliAfiliasi tidak diketahui1
Mohd Hosni bin MahmoodAfiliasi tidak diketahui1
Meralda Rossy SyahdindaUniversitas Airlangga1
Alexander Patera NugrahaUniversitas Airlangga1
Ari TriwardhaniUniversitas Airlangga1
Sherman SalimUniversitas Airlangga1
Michael Josef Kridanto KamadjajaUniversitas Airlangga1
Wiwik Herawati WaluyoUniversitas Airlangga1
Olivia Vivian WidjajaUniversitas Airlangga1
Cinitra AnindyaUniversitas Muhammadiyah Surabaya1
Singgih HarsenoUniversitas Airlangga1
Ahmad Afif DzulfiqarUniversitas Airlangga1
Nisrina Qurrota AiniAfiliasi tidak diketahui1
Adioro SoetojoUniversitas Airlangga1
Paramita Tanjung SariUniversitas Airlangga1
SukatonUniversitas Airlangga1
Fridianty AnggraeniUniversitas Airlangga1
Nadia Dwi MaharaniUniversitas Airlangga1
Ira WidjiastutiUniversitas Airlangga1
Widya SaraswatiUniversitas Airlangga1
SukatonUniversitas Airlangga1
Yashinta RamadhintaUniversitas Airlangga1
Tiffany Josephine HidayatUniversitas Airlangga1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://e-journal.unair.ac.id/MKG/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Burning mouth syndrome caused by xerostomia secondary to amlodipine</dc:title>
	<dc:creator>Noor, Tengku Natasha Eleena binti Tengku Ahmad</dc:creator>
	<dc:subject xml:lang="en-US">amlodipine</dc:subject>
	<dc:subject xml:lang="en-US">burning</dc:subject>
	<dc:subject xml:lang="en-US">dry mouth</dc:subject>
	<dc:subject xml:lang="en-US">military officer</dc:subject>
	<dc:subject xml:lang="en-US">xerostomia</dc:subject>
	<dc:description xml:lang="en-US">Background: Xerostomia, generally referred to as dry mouth, has been identified as a side effect of more than 1,800 drugs from more than 80 groups. This condition is frequently unrecognised and untreated but may affect patients' quality of life and cause problems with oral and medical health, including burning mouth syndrome (BMS). Purpose: The purpose of this case is to discuss how to manage a patient with BMS caused by xerostomia secondary to medication that has been taken by the patient. Case: We reported that a 45-year-old male military officer from the Royal Malaysian Air Force came to Kuching Armed Forces Dental Clinic with dry mouth and a burning sensation since he started taking 10 mg of amlodipine due to his hypertension. After a thorough physical and history examination, we made a diagnosis of burning mouth syndrome (BMS) caused by xerostomia secondary to amlodipine. Case Management: Oral hygiene instructions, diet advice and prescription of Oral7 mouthwash has been given to reduce the symptoms of BMS. The patient has been referred to the general practitioner to reduce his amlodipine dosage from 10 mg to 5 mg (OD) in order to prevent xerostomia, and oral hygiene instructions have been given. A review after two weeks showed significant changes in the oral cavity, and the patient was satisfied as he is no longer feeling the burning sensation and can enjoy his food without feeling difficulty in chewing and swallowing. Conclusion: Adverse drug events are normal in the oral cavity and may have a number of clinical presentations such as xerostomia. Xerostomia can cause many implications as saliva helps in maintaining oral mucosa and has a protective function. The signs of adverse drug incidents in the oral cavity should be identified to oral health care professionals.</dc:description>
	<dc:publisher xml:lang="en-US">Faculty of Dental Medicine, Universitas Airlangga https://fkg.unair.ac.id/en</dc:publisher>
	<dc:date>2020-12-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://e-journal.unair.ac.id/MKG/article/view/20717</dc:identifier>
	<dc:identifier>10.20473/j.djmkg.v53.i4.p187-190</dc:identifier>
	<dc:source xml:lang="en-US">Dental Journal (Majalah Kedokteran Gigi); Vol. 53 No. 4 (2020): December 2020; 187-190</dc:source>
	<dc:source>2442-9740</dc:source>
	<dc:source>1978-3728</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://e-journal.unair.ac.id/MKG/article/view/20717/12754</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2020 Dental Journal (Majalah Kedokteran Gigi)</dc:rights>
</oai_dc:dc>